Ghost Tree Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ghost Tree Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-200,000	Closed	-$1.41M	–	71
2023 Q2	$1.41M	Sell	200,000 -75,000	-27%	-$602K	0.46%	43
2023 Q1	$2.29M	Buy	275,000 +50,000	+22%	+$481K	0.68%	38
2022 Q4	$2.58M	Sell	225,000 -300,000	-57%	-$3.74M	1.1%	25
2022 Q3	$6.62M	Buy	525,000 +200,000	+62%	+$2.57M	1.86%	22
2022 Q2	$3.44M	Sell	325,000 -25,000	-7%	-$258K	1.79%	24
2022 Q1	$5.69M	Buy	+350,000	New	+$5.61M	1.24%	18
2021 Q2	–	Sell	-500,000	Closed	-$5.08M	–	56
2021 Q1	$5.08M	Sell	500,000 -400,000	-44%	-$4.12M	1.2%	28
2020 Q4	$6.71M	Sell	900,000 -1,050,000	-54%	-$5.41M	1.49%	25
2020 Q3	$6.7M	Buy	1,950,000 +50,000	+3%	+$214K	1.94%	18
2020 Q2	$9.05M	Sell	1,900,000 -100,000	-5%	-$399K	2.39%	18
2020 Q1	$4M	Sell	2,000,000 -1,000,000	-33%	-$2.75M	1.06%	21
2019 Q4	$10.3M	Buy	3,000,000 +1,500,000	+100%	+$3.77M	1.97%	18
2019 Q3	$4.3M	Sell	1,500,000 -1,000,000	-40%	-$3.11M	1.1%	30
2019 Q2	$9.47M	Buy	2,500,000 +2,000,000	+400%	+$12M	1.97%	14
2019 Q1	$4.07M	Hold	500,000	–	–	1.06%	32
2018 Q4	$4.04M	Hold	500,000	–	–	1.46%	24
2018 Q3	$3.81M	Buy	+500,000	New	+$3.36M	0.81%	35
2017 Q4	–	Sell	-500,000	Closed	-$2.62M	–	52
2017 Q3	$2.62M	Sell	500,000 -175,000	-26%	-$896K	0.56%	52
2017 Q2	$3.75M	Sell	675,000 -825,000	-55%	-$5.03M	0.78%	47
2017 Q1	$12.6M	Buy	1,500,000 +350,000	+30%	+$2.43M	2.35%	8
2016 Q4	$7.28M	Sell	1,150,000 -650,000	-36%	-$3.38M	1.75%	21
2016 Q3	$7.94M	Buy	1,800,000 +100,000	+6%	+$399K	1.29%	27
2016 Q2	$4.83M	Buy	+1,700,000	New	+$5.28M	1.39%	29
2015 Q4	–	Sell	-225,000	Closed	-$2.56M	–	53
2015 Q3	$2.56M	Buy	225,000 +180,000	+400%	+$2.4M	1.15%	37
2015 Q2	$672K	Buy	+45,000	New	+$512K	0.22%	61

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Ghost Tree Capital's BCRX Position: Q3 2023 in Review

Ghost Tree Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2023, closing a stake of 200,000 shares — an estimated $1.41M sold.

Ghost Tree Capital first reported a position in BCRX in Q2 2015 and held it in 25 quarters. The position peaked at $12.6M in Q1 2017. 233 funds tracked by Wall St. Rank hold BCRX as of Q3 2023.

Ghost Tree Capital reported no remaining BioCryst Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Ghost Tree Capital sold 200,000 BioCryst Pharmaceuticals shares in Q3 2023, an estimated $1.41M.
Ghost Tree Capital first reported a position in BioCryst Pharmaceuticals in Q2 2015 and held it in 25 quarters.
Ghost Tree Capital's BioCryst Pharmaceuticals position peaked at $12.6M in Q1 2017.
233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2023.

Based on Ghost Tree Capital's 13F filing for Q3 2023, filed 14 Nov 2023.